1. LEPROSY (Hansenʼs disease)

2. A Little History … 7/29/1841-2/12/1912
Gerhard Henrik Armauer Hansen was a physician which first identified Mycobacterium leprae as the cause of leprosy in 1873
FYI
7/29/1841-2/12/1912

3. EPIDEMIOLOGY
1. Identification—A chronic bacterial disease of the skin, peripheral ,nerves and (in lepromatous patients) the upper airway.
Two polar forms:
i) lepromatous (multibacillary) leprosy
ii) tuberculoid (paucibacillary) leprosy
Borderline leprosy has features of both polar forms and is more labile.
Indeterminate leprosy
is characterized by hypopigmented maculae with
ill-defined borders; if untreated, it may progress to
tuberculoid, borderline or lepromatous disease.
1. Identification—A chronic bacterial disease of the skin, peripheral
nerves and (in lepromatous patients) the upper airway. The clinical
manifestations of the disease vary in a continuous spectrum between 2
polar forms: i) lepromatous (multibacillary) leprosy: symmetrical and
bilateral nodules, papules, macules and diffuse infiltrations, usually numerous
and extensive; involvement of the nasal mucosa may lead to crusting,
obstructed breathing and epistaxis; ocular involvement leads to iritis and
keratitis; ii) tuberculoid (paucibacillary) leprosy: skin lesions single or few,
sharply demarcated, anaesthesic or hypoaesthesic; bilateral asymmetrical
involvement of peripheral nerves tends to be severe. Borderline leprosy
has features of both polar forms and is more labile. Indeterminate leprosy
is characterized by hypopigmented maculae with ill-defined borders; if
untreated, it may progress to tuberculoid, borderline or lepromatous
disease.

4. EPIDEMIOLOGY Case definition (WHO operational definition)
A case of leprosy is a person having one or more of the following, who has yet to complete a full course of treatment:
● Hypopigmented or reddish skin lesion(s) with definite loss of sensation
● Involvement of the peripheral nerves (definite thickening with loss of
sensation)
● Skin smear positive for acid-fast bacilli.
Case definition (WHO operational definition)
A case of leprosy is a person having one or more of the following, who
has yet to complete a full course of treatment:
● Hypopigmented or reddish skin lesion(s) with definite loss of sensation
● Involvement of the peripheral nerves (definite thickening with loss of
sensation)
● Skin smear positive for acid-fast bacilli.
The operational case definition includes retrieved defaulters with signs
of active disease and relapsed cases who have previously completed a full
course of treatment. It does not include cured persons with late reactions
or residual disabilities.
Clinical diagnosis is based on complete skin examination. Search for
signs of peripheral nerve involvement (hyperesthaesia, anesthaesia, paralysis,
muscle wasting or trophic ulcers) with bilateral palpation of peripheral
nerves (ulnar nerve at the elbow, peroneal nerve at the head of the
fibula and the great auricular nerve) for enlargement and tenderness. Test
skin lesions for sensation (light touch, pinprick, temperature discrimination).
The clinical manifestations can include “reactions” of leprosy, i.e. acute
adverse episodes, which are termed erythema nodosum leprosum in
lepromatous patients and reversal reactions in borderline leprosy.
Differential diagnosis includes many infiltrative skin diseases, including
lymphomas, lupus erythematosus, psoriasis, scleroderma and neurofibromatosis.
Diffuse cutaneous leishmaniasis, some mycoses, myxoedema and
pachydermoperiostosis may resemble lepromatous leprosy, but acid-fast
bacilli are not present. Several skin conditions, such as vitiligo, tinea
versicolor, pityriasis alba, nutritional dyschromia, nevus and scars may
resemble tuberculoid leprosy.

5. EPIDEMIOLOGY
The operational case definition includes retrieved defaulters with signs of active disease and relapsed cases who have previously completed a full course of treatment. It does not include cured persons with late reactions or residual disabilities.

6. EPIDEMIOLOGY
Laboratory criteria include the presence of alcohol-acid-fast bacilli in skin smears (scrape-incision method). Leprosy cases can be classified as follows: - Multibacillary leprosy: more than 5 patches or lesions on the skin - Paucibacillary leprosy: 1 to 5 patches or lesions on the skin.
Laboratory criteria include the presence of alcohol-acid-fast bacilli in skin smears (scrape-incision method).
Leprosy cases can be classified as follows:
- Multibacillary leprosy: more than 5 patches or lesions on the skin
- Paucibacillary leprosy: 1 to 5 patches or lesions on the skin.

7. EPIDEMIOLOGY
2. Infectious agent—Mycobacterium leprae. which cannot be grown in bacteriological media or cell cultures.
2. Infectious agent—Mycobacterium leprae. This cannot be grown in
bacteriological media or cell cultures.

8. EPIDEMIOLOGY 3. Occurrence—
During 2006, persons were diagnosed with leprosy, over half of them in India.Control has improved with the introduction of multidrug therapy (MDT).
WHO has targeted the disease for elimination (less than 1 case/ population) and this has been achieved in all but three(Brazil,Nepal and Tanzania) of the 122 countries endemic in 1985.
Newly recognized cases in the USA are few .Most of these cases are in immigrants and refugees whose disease was acquired in their native countries.
3. Occurrence—During 2002, persons were diagnosed with
leprosy, 90% of them in Brazil, India, Madagascar, Mozambique, Nepal, and in the United Republic of Tanzania.
Control has improved with the introduction of multidrug therapy (MDT). WHO has targeted the disease for elimination (less than 1 case/ population) and this has been achieved in 110 out of the 122 countries endemic in 1985.
Newly recognized cases in the USA are few .Most of these cases are in immigrants and refugees whose disease was acquired in their native countries.

9. EPIDEMIOLOGY
4. Reservoir—Humans are the only significant reservoirs.Feral armadillos, and monkeys have been found naturally affected .
5. Mode of transmission—The disease is in all likelihood transmitted from the nasal mucosa of a patient to the skin and respiratory tract of another person.
Transmission requires close contact.
Although the bacillus can survive up to 7 days in dried nasal secretions, indirect transmission is unlikely.
4. Reservoir—Humans are the only significant reservoirs.
5. Mode of transmission—The disease is in all likelihood transmitted from the nasal mucosa of a patient to the skin and respiratory tract of another person.
Transmission requires close contact.
Although the bacillus can survive up to 7 days in dried nasal secretions, indirect transmission is unlikely.

10. EPIDEMIOLOGY
6. Incubation period—This ranges from 9 months to 20 years, the average is probably 4 years for tuberculoid leprosy and twice that for lepromatous leprosy. The disease is rarely seen in children under age 3;
however, more than 50 cases have been identified in children under 1, the youngest at 10 weeks.
6. Incubation period—This ranges from 9 months to 20 years, the
average is probably 4 years for tuberculoid leprosy and twice that for
lepromatous leprosy. The disease is rarely seen in children under age 3;
however, more than 50 cases have been identified in children under 1, the
youngest at 2.5 months.

11. EPIDEMIOLOGY 7. Period of communicability—
Clinical and laboratory evidence suggest that infectiousness is lost in most instances within a day of treatment with multidrug therapy.
7. Period of communicability—Clinical and laboratory evidence
suggest that infectiousness is lost in most instances within a day of
treatment with multidrug therapy.

12. EPIDEMIOLOGY 8. Susceptibility—
The persistence and form of leprosy depend on the ability to develop effective cell-mediated immunity.
The high prevalence of M. leprae-specific lymphocyte transformation and antibodies specific for M. leprae among close contacts of leprosy patients suggests that infection is frequent, yet clinical disease occurs in only a small proportion of such close contacts.
The immunological lepromin test used earlier
should be reserved for research activities.
8. Susceptibility—The persistence and form of leprosy depend on the
ability to develop effective cell-mediated immunity. The high prevalence
of M. leprae-specific lymphocyte transformation and antibodies specific
for M. leprae among close contacts of leprosy patients suggests that
infection is frequent, yet clinical disease occurs in only a small proportion
of such close contacts. The immunological lepromin test used earlier
should be reserved for research activities.

13. A. PREVENTIVE MEASURES
The availability of effective and time-limited treatment, with rapid elimination of infectiousness, has changed management from societal isolation to ambulatory treatment.
Hospitalization should now be limited only to cases such as the surgical correction of deformities, treatment of ulcers resulting from anaesthesia, and severe leprosy reactions.
9. Methods of control—The availability of effective and time-limited
ambulatory treatment, with rapid elimination of infectiousness, has
changed management. Hospitalization should now be limited only to cases
such as the surgical correction of deformities, treatment of ulcers resulting
from anaesthesia, and severe leprosy reactions.

14. A. PREVENTIVE MEASURES Early detection and treatment of cases.
Dapsone chemoprophylaxis is not recommended (limited effectiveness and danger of resistance).
A. Preventive measures: Early detection and treatment of cases.
Dapsone chemoprophylaxis is not recommended (limited effectiveness
and danger of resistance).
The availability of drugs effective in treatment and in rapid
elimination of infectiousness, such as rifampicin, has changed the
management of the patient with leprosy, from societal isolation
with attendant despair, to ambulatory treatment without the
need for hospitalization.
1) Health education together with counselling of patients and
relatives must stress the availability of effective multidrug
therapy, the absence of infectivity of patients under continuous
treatment and the prevention of physical and social
disabilities.
2) BCG vaccination can induce protection against the tuberculoid
form of the disease; this is part of the control of
tuberculosis in some countries and must not be undertaken
specifically to prevent leprosy.

15. A. PREVENTIVE MEASURES
Health education together with counseling of patients and relatives must stress the availability of effective multidrug therapy, the absence of infectivity of patients under continuous treatment and the prevention of physical and social disabilities.
BCG vaccination can induce protection against both the tuberculoid and lepromatous forms of the disease.

16. B. CONTROL OF PATIENT, CONTACTS AND THE IMMEDIATE ENVIRONMENT
1) Report to local health authority: obligatory in many countries and desirable in all, Class 2. 2) Isolation: Unnecessary.Reducing contact with known leprosy patients is of dubious value and can lead to stigmatization. No restrictions in employment or attendance at school are indicated.3) Quarantine: Not applicable.4) Immunization of contacts: Not recommended 5) Investigation of contacts and source of infection: Examination of close contacts can be useful.
B. Control of patient, contacts and the immediate environment:
1) Report to local health authority: Case report obligatory in
many and countries and desirable in all, Class 2 (see Reporting).
2) Isolation: Reducing contact with known leprosy patients is of
dubious value and can lead to stigmatization. No restrictions
in employment or attendance at school are indicated.
3) Quarantine: Not applicable.
4) Immunization of contacts: Not recommended
5) Investigation of contacts and source of infection: The initial
examination of close contacts can be useful.

17. B. CONTROL OF PATIENT, CONTACTS AND THE IMMEDIATE ENVIRONMENT
6) Specific treatment:
Combined chemotherapy regimens are essential.
The duration of therapy for multibacillary leprosy can be shortened to 12 months from the previously recommended 24 months.
Patients under treatment should be monitored for drug side-effects, for leprosy reactions and for development of trophic ulcers.
Some complications may need to be treated in a referral center.
6) Specific treatment: Combined chemotherapy regimens are
essential. The duration of therapy for multibacillary leprosy
can be shortened to 12 months from the previously recommended
24 months. Patients under treatment should be
monitored for drug side-effects, for leprosy reactions and for
development of trophic ulcers. Some complications may
need to be treated in a referral center. Ambulatory treatment
by multidrug therapy (MDT) is given according to case
classification.

18. B.CONTROL OF PATIENT, CONTACTS AND THE IMMEDIATE ENVIRONMENT
Ambulatory treatment by multidrug therapy (MDT) is given according to case classification.
Adults with multibacillary leprosy(wih more than 5 skin lesions): The standard WHO regimen is a combination of the following for 12 months:
» Rifampicin: 600 mg once a month
» Dapsone: 100 mg once a day
» Clofazimine: 50 mg once a day and 300 mg
once a month.
Adults with multibacillary leprosy: the standard regimen
is a combination of the following for 12 months:
» Rifampicin: 600 mg once a month
» Dapsone: 100 mg once a day
» Clofazimine: 50 mg once a day and 300 mg once a month.
Adults with paucibacillary leprosy: the standard regimen
is a combination of the following for 6 months:
» Dapsone: 100 mg once a day.

19. B.CONTROL OF PATIENT, CONTACTS AND THE IMMEDIATE ENVIRONMENT
Adults with paucibacillary leprosy(adults with 2-5 skin lesions): The standard WHO regimen is a combination of the following for 6 months: » Rifampicin: 600 mg once a month » Dapsone: 100 mg once a day. Adults with a single lesion :The standard WHO regimen is a combination of the following,given once: Rifampici :600mg. Ofloxacin:400mg. Minocycline:100mg.

20. B. CONTROL OF PATIENT, CONTACTS AND THE IMMEDIATE ENVIRONMENT
Children must receive appropriately scaled-down doses (in child blister-packs).
Patients must be advised to complete the full course of treatment and to seek care in the event of drug side-effects (allergic reaction) and immunological reactions (neuritis leading to damage of the peripheral nerve trunks).
Multiple drug therapy is available free of charge through WHO. MDT drugs must be given in blister packs, free of charge, to all patients.
Children must receive appropriately scaled-down doses (in
child blister-packs).
Patients must be advised to complete the full course of
treatment and to seek care in the event of drug side-effects
(allergic reaction) and immunological reactions (neuritis leading
to damage of the peripheral nerve trunks).
Multiple drug therapy is available free of charge through
WHO. MDT drugs must be given in blister packs, free of
charge, to all patients.

21. B. CONTROL OF PATIENT, CONTACTS AND THE IMMEDIATE ENVIRONMENT
Treatment of reactions:
Corticosteroids are the drugs of choice for the treatment of reactions associated with neuritis.
Clofazimine is the drug of choice for the management of recurrent ENL reactions.Its use in MDT has significantly reduced the frequency and severity of ENL reactions worldwide.
Treatment of reactions: Corticosteroids are drugs of
choice in the management of reactions associated with
neuritis. During the 1960s thalidomide was reintroduced as
treatment for Erythema nodosum leprosum (ENL). In view of
the risk of deformed births among users, and despite its
possible usefulness for other conditions, thalidomide has no
place in the treatment of leprosy. Clofazimine is the drug of
choice for the management of recurrent ENL reactions. Its
presence in multidrug therapy (MDT) has significantly reduced
the frequency and severity of ENL reactions worldwide.

22. C.DISASTER IMPLICATIONS
Any interruption of treatment schedule is serious .During wars,diagnosis and treatment of leprosy patients has often been neglected.